Digestive Health

Health areas

In a recent study, NORDBIOTIC™ probiotic strains demonstrated a beneficial effect on the physiological functions of the digestive system.

The results of this randomized, double-blind, placebo-controlled trial involving adult participants with diarrhea-predominant irritable bowel syndrome (IBS-D) indicated that supplementation with a product containing NORDBIOTIC™ Lactobacillus, Bifidobacterium, and Streptococcus thermophilus strains positively influenced intestinal comfort compared with placebo. The probiotic was well tolerated and contributed to an improvement in quality of life. These findings suggest that a multi-strain probiotic formulation may provide benefits for adults suffering from IBS-D.

A preparation containing a blend of Bifidobacterium and Lactobacillus strains was shown to improve quality of life, while a synbiotic formulation had a beneficial impact on overall gut health. A systematic review and meta-analysis published in 2020 demonstrated that high-dose single-strain probiotic preparations, particularly those containing Bifidobacterium or Lactobacillus strains, may improve quality of life in patients with IBS.

Therefore, the primary objective of this research project is to evaluate the effects of supplementation with single-strain probiotics containing Bifidobacterium lactis or Bacillus coagulans on the physiological functions of individuals with IBS or SIBO (Small Intestinal Bacterial Overgrowth).

Table 1. Specification of strains (NORDBIOTIC™) used in the evaluated probiotic preparation.

Strain	CFU Per Capsule	Number
Bifidobacterium breve	2.08 x 10⁸	BB010
Bifidobacterium longum	1.39 x 10⁸	BL020
Bifidobacterium bifidum	1.39 x 10⁸	BF030
Bifidobacterium lactis	4.17 x 10⁸	BL040
Lactobacillus rhamnosus	5.56 x 10⁸	LR110
Lactobacillus paracasei	2.08 x 10⁸	LPC100
Lactobacillus acidophilus	2.08 x 10⁸	LA120
Lactobacillus casei	2.08 x 10⁸	LC130
Lactobacillus plantarum	2. 08 x 10⁸	LP140
Streptococcus thermophilus	2.08 x 10⁸	ST250
Total CFU	2.50 x 10⁹

All the strains are deposited in the patent deposit of the Leibniz Institute DSMZ—German Collection of Microorganisms and Cell Cultures. CFU = colony forming units.

Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B. Nutrients. 2021 Feb 26;13(3):756
The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study

Irritable bowel syndrome (IBS) is one of the most common, yet still not fully understood, gastrointestinal disorders in adults

One suspected etiology involves intestinal dysbiosis, i.e. both quantitative and qualitative alterations in the intestinal microbiota composition, which affect the gut-brain axis.

The formulation composed of a mixture of Bifidobacterium and Lactobacillus strains reduced the pain severity and improved the quality of life, whereas the synbiotic formulation effectively improved bloating and had a beneficial effect on the general condition of the intestines. A systematic review and meta-analysis published in 2020 showed that high doses of single-strain formulations, particularly those containing Bifidobacterium or Lactobacillus strains, may be more effective in IBS patients. Other reports demonstrated a high efficacy of the new-generation probiotic Bacillus coagulans in IBS. Therefore, the main objective of this research project is to assess the efficacy of single-strain probiotics containing Bifidobacterium lactis or Bacillus coagulans in patients with IBS and SIBO.

Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. J Infect. 2018, 76(2):111-120

FAO/WHO Consultations and Workshops. Safety assessment of foods derived from genetically modified microorganisms. Report of a Joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology, 200, 11–29

Ford, A.C.; Harris, L.A.; Lacy, B.E.; Quigley, E.M.M.; Moayyedi, P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018, 48: 1044–1060

Skrzydło-Radomańska B., Prozorow-Król B., Cichoż-Lach H., et al. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients 2021,13:756

Skrzydło-Radomańska B., Prozorow-Król B., Cichoż-Lach H., et al. The effectiveness of synbiotic preparation containing Lactobacillus and Bifidobacterium probioticstrains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome-a randomized double-blind, placebo-controlled study. Nutrients 2020, 12:1999

Li B., Liang L.; Deng, H.; Guo, J.; Shu, H.; Zhang, L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-Analysis. Front. Pharmacol. 2020, 11, 332

Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (Baltimore). 2021, 22;100(3):e23641

NORDBIOTIC™ strains preparation

Subjects of our research in IBS and SIBO:

B. lactis NORDBIOTIC™ BI040
B coagulans NORDBIOTIC™ BC300

Our studies